This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sawada, N. Articles by Ishitsuka, H. Search for Related Content PubMed PubMed Citation Articles by Sawada, N. Articles by Ishitsuka, H.

X-Ray Irradiation Induces Thymidine Phosphorylase and Enhances the Efficacy of Capecitabine (Xeloda) in Human Cancer Xenografts

Cytostatics Group, Nippon Roche Research Center, Kanagawa 247-8530, Japan

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Thymidine phosphorylase (dThdPase) is an essential enzyme for the activation of the cytostatics capecitabine (N⁴-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) and its intermediate metabolite 5'-deoxy-5-fluorouridine (5'-dFUrd) to 5-fluorouracil (5-FUra) in tumors. We observed previously that several cytokines and cytostatics up-regulated dThdPase expression and consequently enhanced the efficacy of capecitabine and 5'-dFUrd. In the present study, we found that X-ray irradiation also up-regulated dThdPase expression in several human cancer xenografts. A single-dose local irradiation at 5 Gy increased dThdPase levels by up to 13-fold at 9 days after the irradiation. Whole-body irradiation also up-regulated dThdPase in a tumor, but it did not increase the enzyme level in the liver. We also observed that the irradiation increased the levels of human tumor necrosis factor (TNF-), which is an up-regulator of dThdPase, prior to the dThdPase up-regulation. These results indicate that X-ray irradiation might increase dThdPase levels indirectly through the human TNF- in the tumor tissue. In the WiDr colon and MX-1 mammary human cancer xenograft models, the combination of a single local X-ray irradiation with either capecitabine or 5'-dFUrd was much more effective than either radiation or chemotherapy alone. In contrast, treatment with X-ray irradiation and 5-FUra in combination showed no clear additive effects. Combined modality treatment of cancer patients with capecitabine and X-ray irradiation would have greater potential usefulness than conventional radiochemotherapy with 5-FUra.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Capecitabine is a novel fluoropyrimidine carbamate that is being used clinically for the treatment of breast cancer patients who have failed paclitaxel and anthracycline regimens (1) , and it is being assessed for the treatment of other types of cancer. It generates the active drug 5-FUra² selectively in tumors by three enzymes located in the liver and in tumors; the final step is the conversion of the intermediate metabolite 5'-dFUrd to 5-FUra by dThdPase in tumors (2 , 3) . This conversion appeared to be a rate-limiting step for the efficacy of capecitabine. We observed that the conversion was insufficient in a human cancer xenograft line, which was refractory to capecitabine in in vivo therapy (4) , and that the susceptibility of human cancer xenografts to 5'-dFUrd correlated with their levels of dThdPase expression (5) . Therefore, the efficacy of capecitabine and its intermediate 5'-dFUrd would be optimized by selecting patients who have tumors with high levels of dThdPase expression. Another useful approach for optimizing capecitabine and 5'-dFUrd therapy would be a combination therapy with their rational partners, such as up-regulators of dThdPase.

Previously, we reported that several cytokines, such as IL-1, TNF-, IFN- up-regulated dThdPase mRNA expression in human cancer cells and increased the susceptibility of the tumor cells to 5'-dFUrd (6) . Furthermore, we observed in human cancer xenograft models that the anticancer drugs, such as paclitaxel and docetaxel, increased tumor levels of dThdPase expression and consequently showed a synergistic antitumor activity with capecitabine (7) . We suggested that the taxanes might increase dThdPase level indirectly through the up-regulation of TNF-, because the taxanes simultaneously increased tumor levels of human TNF-. Several factors have been reported to up-regulate TNF-. It is, therefore, of interest to investigate whether factors other than taxanes increase dThdPase levels in tumors and make the tumors more susceptible to capecitabine. In the present study, we found that X-ray irradiation, which is known to up-regulate TNF- (8, 9, 10) , indeed increased tumor levels of both TNF- and dThdPase. Consequently, the efficacy of X-ray irradiation and either capecitabine or 5'-dFUrd in combination was much better than either treatment in human cancer xenograft models. We describe these results and discuss the potential of this rational combination therapy for cancer patients with either capecitabine or 5'-dFUrd and X-ray irradiation.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Chemicals.
Capecitabine and its intermediate metabolite 5'-dFUrd were obtained from F. Hoffmann-La Roche (Basle, Switzerland). 5-FUra was purchased from Kyowa Hakko Co. (Tokyo, Japan). 2,2'-Anhydro-5-ethyluridine was synthesized by the method described elsewhere (11) .

Capecitabine and 5'-dFUrd were dissolved or suspended in 40 mM citrate buffer (pH 6.0) containing 5% gum arabic as the vehicle and then administered p.o. to mice. 5-FUra was dissolved in saline and given i.p. The fluoropyrimidines used in combination therapy were given at their maximum tolerated doses (4 , 5) as described in the tables.

Animals.
Male and female BALB/c nu/nu mice, 5 or 6 weeks of age, were obtained from SLC, Inc. (Hamamatsu, Japan).

Tumors.
The human cancer lines used were obtained from the following institutions: colon cancer WiDr, HT-29, and cervix cancer SIHA from the American Type Culture Collection (Rockville, MD); gastric cancer MKN-45 from Immunobiological Laboratories, (Fujioka, Japan); and mammary cancer MX-1 from Dr. T. Tashiro (Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan). MX-1 was maintained by continuous in vivo passage in BALB/c nu/nu mice. The other cancer cell lines were maintained in in vitro cultures.

Human Cancer Xenograft Model.
A single-cell suspension (5 to 10 x 10⁶ cells/mouse) of WiDr, HT-29, MKN-45, and SIHA or small pieces of MX-1 was inoculated s.c. into nude mice. The experiments were started when the tumor volume reached 0.2–0.5 cm³. The number of animals in each experiment group was specified in the legend of each table and figure. To evaluate the antitumor effect of X-ray irradiation, we measured tumor size and body weight at the time the tumor tissues were excised for measuring dThdPase levels. The tumor volume was estimated by using the following equation, , where a and b are tumor length and width, respectively. The tumor volume change was calculated as expressed by the formula V_T - V_O, where V_T is the mean volume on any given day and V_O is the mean volume at the start of the treatment. To evaluate the efficacy of X-ray irradiation or X-ray irradiation combined with fluoropyrimidines, tumor size and body weight were measured twice a week. Carcass body weight was calculated by subtracting the tumor weight, which was estimated from tumor volume, from the body weight. The tumor volume was plotted as a function of time. From these lines, mean estimates were made of growth delay (T_2.5), where T_2.5 is the time taken for a tumor to grow 2.5-fold of the volume on the first day of treatment.

All animal experiments were conducted in accordance with the "Guidelines for the Care and Use of Laboratory Animals in the Nippon Roche Research Center."

X-Ray Irradiation.
Local X-ray irradiation with tumor or whole-body irradiation was carried out by using an X-ray unit (Hitachi X-ray unit, model MBR-1520R with 0.5 mm Al/0.1 mm Cu filter, 100 kVp, 1.33 Gy/min). Mice bearing the tumors were injected i.p. with pentobarbital (45–55 mg/kg) as an anesthetic agent 20 min before the irradiation to be immobilized. In combination therapy, either capecitabine, 5'-dFUrd, 5-FUra, or the vehicle was administered 1 h before irradiation.

dThdPase Assays.
Tissues were homogenized in 10 mM Tris buffer (pH 7.4) containing 15 mM NaCl, 1.5 mM MgCl₂, and 50 µM potassium phosphate with a glass homogenizer. The homogenate of tumor tissues was then centrifuged at 10,000 x g for 20 min at 4°C, and the supernatants were stored at -80°C until use. For the measurement of dThdPase activity in the liver, the homogenate of liver was centrifuged at 105,000 x g for 90 min at 4°C. The supernatants were then dialyzed overnight at 4°C against 20 mM potassium phosphate buffer (pH 7.4) containing 1 mM -mercaptoethanol and stored at -80°C until use. The protein concentration was determined by the methods of Lowry et al. (12) . The dThdPase level of tumors was measured by ELISA with monoclonal antibodies specific to human dThdPase, as described previously by Nishida et al. (13) . One unit corresponds to the dThdPase level of the standard enzyme solution (extracts of human colon cancer xenograft HCT 116), which phosphorolyzes 5'-dFUrd to 5-FUra at the rate of 1 µg 5-FUra/h, and the dThdPase levels measured correlated well with those measured by an enzyme activity assay (6 , 13) . The monoclonal antibodies were not cross-reacted with mouse dThdPase. Because uridine phosphorylase also phosphorolyzes 5'-dFUrd to 5-FUra, mouse dThdPase activity in the livers was measured by the method described by Eda et al. (6) , in the presence of 1 mM 2, 2'-anhydro-5-ethyluridine, an uridine phosphorylase-specific inhibitor (14) .

TNF- Assays.
The supernatants prepared from tumor tissues were examined for their levels of TNF- with the ELISA method. Human TNF- was measured using the Quantikine ELISA kit (R&D systems). The ELISA assay is specific for only human TNF-.

Statistical Analysis.
Tumor volume change, carcass body weight, and levels of dThdPase were analyzed using Student’s t test or the Mann-Whitney U test, as described in the legends of the tables and figures. Differences were considered to be significant when P < 0.05.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
dThdPase and TNF- Up-Regulation.
Table 1 shows the expression of dThdPase levels in tumor tissues after single-dose local X-ray irradiation at 2.5 or 5 Gy in five human cancer xenograft models. An up-regulation of dThdPase was observed in four of the five human cancer xenograft models studied. We further investigated kinetics of the dThdPase up-regulation by single-dose local X-ray irradiation at 2.5 or 5 Gy in the WiDr human colon tumor xenograft model (Fig. 1) . The dThdPase levels in the tumor tissue were maximally increased on day 9 and then gradually decreased up to day 18. After the irradiation, increased tumor levels of human TNF- expression first were seen, which appears to be followed by the dThdPase up-regulation (Fig. 2) . Because the dThdPase and TNF- levels were detected by the ELISA with monoclonal antibodies specific to human dThdPase and TNF-, respectively, the measured levels of these two factors corresponded to those of the factors produced in the human cancer cells. The dThdPase up-regulation correlated with the TNF- up-regulation in each mouse studied (Fig. 3) . X-ray irradiation might increase dThdPase levels indirectly through the TNF- up-regulation. In contrast, human IL-1, which also up-regulates dThdPase, was not elevated by the irradiation (data not shown).

View larger version (22K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Effect of local X-ray irradiation on dThdPase up-regulation of the WiDr human colon cancer tumor in nude mice. Mice bearing WiDr tumors were randomized into groups of three mice each, and single-dose local X-ray irradiation was given on day 0. Mice were sacrificed, and tumor tissues were excised at various days after X-ray irradiation. Data points, mean dThdPase values; bars, SD. *, significantly different from control at each points; P < 0.05 by Student’s t test. , control; , 2.5 Gy; •, 5 Gy.

View larger version (22K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Effect of local X-ray irradiation on human TNF- of the WiDr human colon cancer tumor in nude mice. The samples used in the experiment shown Fig. 1 were examined for their levels of human TNF-. Data points, mean human TNF- values; bars, SD. Human TNF- levels below the detection limit were assigned as 80 pg/g of tissue. , control; , 2.5 Gy; •, 5 Gy.

View larger version (19K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Correlation between dThdPase and human TNF- of the WiDr tumor tissues after local X-ray irradiation. Data points, data on days 6 and 12 from individual mice tested in the experiment shown Figs. 1 and 2 . Significance was calculated by assigning the value for the human TNF- level below the detection limit as 80 pg/g of tissue. , day 6; •, day 12.

Combination Therapy.
It is expected that the preferential effect of X-ray irradiation on enzyme up-regulation in tumor tissues would result in increasing their susceptibility to capecitabine treatment. To ascertain this possibility, we conducted combination therapy with local X-ray irradiation and capecitabine in the WiDr human colon cancer xenograft, which is a cell line refractory to fluoropyrimidines because of low dThdPase expression. Capecitabine, 5'-dFUrd, and 5-FUra were given at their maximum tolerated dose, whereas the local X-ray irradiation was given at 5 Gy once. The efficacy of local X-ray irradiation in combination with either capecitabine or 5'-dFUrd was much higher than that of either treatment, and tumor regression was observed only in the combination groups (Table 2) . When delay of tumor growth (T_2.5) is compared, the efficacy of the combination appears to be more than just additive. In contrast, local X-ray irradiation and 5-FUra in combination showed no clear additive activity. On the other hand, toxicity in terms of weight loss does not appear to be increased in mice given local X-ray irradiation and capecitabine, and the degree of toxicity was similar to that in mice given local X-ray irradiation and 5-FUra. Local X-ray irradiation and either capecitabine or 5'-dFUrd in combination also showed much better antitumor activity than either treatment in the other tumor model studied, the MX-1 human mammary cancer xenograft model (Table 3) .

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

The up-regulation of dThdPase was preceded by the TNF- up-regulation in the X-ray irradiated mice as well as by the anticancer drug taxanes in the previous study (7) , and the degree of the up-regulation of TNF- was correlated with the dThdPase up-regulation in each mouse studied. In one human cancer xenograft model studied (SIHA cervical cancer), dThdPase levels were not increased after the X-ray irradiation, and human TNF- levels were below the detection limit (data not shown). We have reported that several cytokines up-regulate dThdPase, such as TNF-, IL-1, and IFN- in vitro (6) . These results indicate that X-ray irradiation might up-regulate dThdPase indirectly through the human TNF- in the tumor tissue, although the mechanism of dThdPase up-regulation should be investigated further. X-ray irradiation was reported to up-regulate IL-1 in cell cultures (15) . However, it is not likely to be involved in the up-regulation of dThdPase in the present study, because tumor levels of IL-1 was not changed at 1–18 days after the X-ray irradiation (data were not shown). X-ray irradiation was also reported to induce TNF- for 20 h in tumor cell cultures (8) . The up-regulation of TNF- in the WiDr tumors was, however, observed at several days after X-ray irradiation. X-ray irradiation might affect host stromal cells in tumor tissues, resulting in the up-regulation of TNF- in tumor cells and consequently that of dThdPase. These processes may take 6 days. We also observed a similar delay in the dThdPase up-regulation by taxanes (7) . Either docetaxel or paclitaxel up-regulated both TNF- and dThdPase in human cancer xenografts at 4 or 6 days after their administration.

The efficacy of X-ray irradiation combined with either capecitabine or 5'-dFUrd was much higher than that of either treatment alone in the human cancer xenograft models studied. Their efficacy in tumor growth inhibition appeared to be additive, but the combination delayed tumor growth to a much greater extent than did either treatment alone. X-rays might also enhance the efficacy of capecitabine and 5'-dFUrd through the up-regulation of dThdPase in tumors. Previously, we observed similar results showing that the efficacy of X-ray irradiation and 5'-dFUrd in combination was synergistic in the mice bearing murine colon 26 carcinoma (16) . X-ray irradiation would be a rational partner of chemotherapy with capecitabine and with its intermediate metabolite 5'-dFUrd. In contrast, although 5-FUra has been reported to enhance cell killing by radiation in some in vitro studies and in several animal tumor models (17, 18, 19) , the efficacy of 5-FUra and radiation had no clear additive effect in the present study. On the basis of the prior studies, 5-FUra has been used in combination therapy with radiation for the treatment of squamous cell carcinoma (20) . From the present study, we may conclude that combined modality treatment of cancer patients with either capecitabine or 5'-dFUrd and X-ray would have greater potential usefulness than the conventional radiochemotherapy with 5-FUra.

In these days, suicide gene therapy of cancer, which consists of gene transfection for a prodrug activation enzyme and therapy with the prodrug, has been investigated, such as the combination with the cytosine deaminase gene and 5-fluorocytosine and those with the herpes simplex virus thymidine kinase gene and ganciclovir (21, 22, 23) . In this approach, the prodrugs are expected to be activated to their corresponding active drugs only in cells transfected with the prodrug activation enzymes. The combination with dThdPase and capecitabine therapy would be an additional candidate for suicide gene therapy. However, this approach has not yet become reality, because a technology of gene transfection to tumor cells in tissues has not yet been established. In the present study, we demonstrated that X-ray irradiation induced the prodrug activation enzyme dThdPase selectively in tumor tissues. The combination with the dThdPase up-regulation by X-ray irradiation and capecitabine therapy would be an alternative for suicide gene therapy.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Cytostatics group, Nippon Roche Research Center, 200, Kajiwara, Kamakura, Kanagawa 247-8530, Japan. Phone: 81-467-47-2220; Fax: 81-467-45-6782; E-mail; hideo.ishitsuka{at}roche.com

² The abbreviations used are: 5-FUra, 5-fluorouracil; 5'-dFUrd, 5'-deoxy-5-fluorouridine; TNF, tumor necrosis factor; IL, interleukin.

Received 4/20/99; revised 7/27/99; accepted 8/ 2/99.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Blum J. L., Jones S. E., Buzdar A. U., LoRusso P. M., Kuter I., Vogel C., Osterwalder B., Burger H. U., Brown C. S., Griffin T. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol., 17: 485-493, 1999.[Abstract/Free Full Text]
2. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., Simma N. Umeda, I., Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 34: 1274-1281, 1998.
3. Kono A., Hara Y., Sugata S., Karube Y., Matsushima Y., Ishitsuka H. Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem. Pharm. Bull. (Tokyo), 31: 175-178, 1983.[Medline]
4. Ishikawa T., Utoh M., Sawada N., Nishida M., Fukase Y., Sekiguchi F., Ishitsuka H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol., 55: 1091-1097, 1998.[Medline]
5. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res., 58: 685-690, 1998.[Abstract/Free Full Text]
6. Eda H., Fujimoto K., Watanabe S., Ura M., Hino A., Tanaka Y., Wada K., Ishitsuka H. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol., 32: 333-338, 1993.[Medline]
7. Sawada N., Ishikawa T., Fukase Y., Nishida M., Yoshikubo T., Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res., 4: 1013-1019, 1998.[Abstract]
8. Hallahan D. E., Spriggs D. R., Beckett M. A., Kufe D. W., Weichselbaum R. R. Increased tumor necrosis factor mRNA after cellular exposure to ionizing radiation. Proc. Natl. Acad. Sci. USA, 86: 10104-10107, 1989.[Abstract/Free Full Text]
9. Sherman M. L., Datta R., Hallahan D. E., Weichselbaum R. R., Kufe D. W. Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J. Clin. Investig., 87: 1794-1797, 1991.
10. Hallahan D. E., Haimovitz-Friedman A., Kufe D. W., Fuks Z., Weichselbaum R. R. The role of cytokines in radiation oncology. Important Adv. Oncol., : 71-80, 1993.
11. Veres Z., Szabolcs A., Szinai I., Denes G., Kajtar-Peredy M., Ötvös L. 5-Substituted-2,2'-anhydrouridines, potent inhibitors of uridine phosphorylase. Biochem. Pharmacol., 34: 1737-1740, 1985.[Medline]
12. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.[Free Full Text]
13. Nishida M., Hino A., Mori K., Matsumoto T., Yoshikubo T., Ishitsuka H. Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol. Pharm. Bull. (Tokyo), 19: 1407-1411, 1996.
14. Iigo M., Nishikata K., Nakajima Y., Szinai I., Veres Z., Szabolcs A., Clercq E. D. Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine. Biochem. Pharmacol., 39: 1247-1253, 1990.[Medline]
15. Woloschak G. E., Chang-Liu C. M., Jones P. S., Jones C. A. Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation. Cancer Res., 50: 339-344, 1990.[Abstract/Free Full Text]
16. Ishikawa T., Tanaka Y., Ishitsuka H., Ohkawa T. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. Jpn. J. Cancer Res., 80: 583-591, 1989.[Medline]
17. Nakajima Y., Miyamoto T., Tanabe M., Watanabe I., Terasima T. Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays. Cancer Res., 39: 3763-3767, 1979.[Abstract/Free Full Text]
18. Weinberg M. J., Rauth A. M. 5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 13: 1691-1699, 1987.[Medline]
19. McGinn C. J., Shewach D. S., Lawrence T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.[Abstract/Free Full Text]
20. Pu A. T., Robertson J. M., Lawrence T. S. Current status of radiation sensitization by fluoropyrimidines. Oncology (Huntingt.), 9: 707-714, 1995.[Medline]
21. Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.[Abstract/Free Full Text]
22. Mullen C. A., Coale M. M., Lowe R., Blaese R. M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res., 54: 1503-1506, 1994.[Abstract/Free Full Text]
23. Freeman S. M., Whartenby K. A., Freeman J. L., Abboud C. N., Marrogi A. J. In situ use of suicide gene for cancer therapy. Semin. Oncol., 23: 31-45, 1996.[Medline]

This article has been cited by other articles:

				Y. Sakurai, I. Yoshida, S. Kamoshida, K. Inaba, J. Isogaki, Y. Komori, I. Uyama, and Y. Tsutsumi Effects of Combined Administration of DPD-Inhibitory Oral Fluoropyrimidine, S-1, Plus Paclitaxel on Gene Expressions of Fluoropyrimidine Metabolism-Related Enzymes in Human Gastric Xenografts Ann. Surg. Oncol., August 1, 2008; 15(8): 2301 - 2309. [Abstract] [Full Text] [PDF]

				M. Findlay, G. von Minckwitz, and A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann. Onc., February 1, 2008; 19(2): 212 - 222. [Abstract] [Full Text] [PDF]

				S. S. Lee, S.-B. Kim, S.-I. Park, Y. H. Kim, J.-S. Ryu, H.-Y. Song, J. H. Shin, H. Y. Jung, G. H. Lee, K. D. Choi, et al. Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 829 - 835. [Abstract] [Full Text] [PDF]

				D. S. Shewach and T. S. Lawrence Antimetabolite Radiosensitizers J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050. [Abstract] [Full Text] [PDF]

				J-P Machiels, C Sempoux, P Scalliet, J-C Coche, Y Humblet, E Van Cutsem, J Kerger, J-L Canon, M Peeters, S Aydin, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann. Onc., April 1, 2007; 18(4): 738 - 744. [Abstract] [Full Text] [PDF]

				D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]

				C. Rodel, T. Liersch, R. M. Hermann, D. Arnold, T. Reese, M. Hipp, A. Furst, N. Schwella, M. Bieker, G. Hellmich, et al. Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer J. Clin. Oncol., January 1, 2007; 25(1): 110 - 117. [Abstract] [Full Text] [PDF]

				A Carmona-Bayonas Concurrent radiotherapy and capecitabine, followed by high-dose methotrexate consolidation, provided effective palliation in a patient with leptomeningeal metastases from breast cancer Ann. Onc., January 1, 2007; 18(1): 199 - 200. [Full Text] [PDF]

				K. Gelmon, A. Chan, and N. Harbeck The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer Oncologist, September 1, 2006; 11(suppl_1): 42 - 51. [Abstract] [Full Text] [PDF]

				S. Liekens, A. Bronckaers, A.-I. Hernandez, E.-M. Priego, E. Casanova, M.-J. Camarasa, M.-J. Perez-Perez, and J. Balzarini 5'-O-Tritylated Nucleoside Derivatives: Inhibition of Thymidine Phosphorylase and Angiogenesis Mol. Pharmacol., August 1, 2006; 70(2): 501 - 509. [Abstract] [Full Text] [PDF]

				E. H. Slager, M. W. Honders, E. D. van der Meijden, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, M. G. D. Kester, I. Jedema, W. A. E. Marijt, M. R. Schaafsma, R. Willemze, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer Blood, June 15, 2006; 107(12): 4954 - 4960. [Abstract] [Full Text] [PDF]

				R. Glynne-Jones, J. Dunst, and D. Sebag-Montefiore The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann. Onc., March 1, 2006; 17(3): 361 - 371. [Abstract] [Full Text] [PDF]

				B. G. Czito, C. G. Willett, J. C. Bendell, M. A. Morse, D. S. Tyler, N. H. Fernando, C. R. Mantyh, G. C. Blobe, W. Honeycutt, D. Yu, et al. Increased Toxicity With Gefitinib, Capecitabine, and Radiation Therapy in Pancreatic and Rectal Cancer: Phase I Trial Results J. Clin. Oncol., February 1, 2006; 24(4): 656 - 662. [Abstract] [Full Text] [PDF]

				A. De Paoli, S. Chiara, G. Luppi, M. L. Friso, G. D. Beretta, S. Del Prete, L. Pasetto, M. Santantonio, E. Sarti, G. Mantello, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study Ann. Onc., February 1, 2006; 17(2): 246 - 251. [Abstract] [Full Text] [PDF]

				R. Glynne-Jones, D. Sebag-Montefiore, T. S. Maughan, S. J. Falk, and A. C. McDonald A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer Ann. Onc., January 1, 2006; 17(1): 50 - 56. [Abstract] [Full Text] [PDF]

				C. Blanquicett, M. W. Saif, D. J. Buchsbaum, M. Eloubeidi, S. M. Vickers, D. C. Chhieng, M. D. Carpenter, J. C. Sellers, S. Russo, R. B. Diasio, et al. Antitumor Efficacy of Capecitabine and Celecoxib in Irradiated and Lead-Shielded, Contralateral Human BxPC-3 Pancreatic Cancer Xenografts: Clinical Implications of Abscopal Effects Clin. Cancer Res., December 15, 2005; 11(24): 8773 - 8781. [Abstract] [Full Text] [PDF]

				M. W. Saif, M. A. Eloubeidi, S. Russo, A. Steg, J. Thornton, J. Fiveash, M. Carpenter, C. Blanquicett, R. B. Diasio, and M. R. Johnson Phase I Study of Capecitabine With Concomitant Radiotherapy for Patients With Locally Advanced Pancreatic Cancer: Expression Analysis of Genes Related to Outcome J. Clin. Oncol., December 1, 2005; 23(34): 8679 - 8687. [Abstract] [Full Text] [PDF]

				B. T. Hennessy, A. M. Gauthier, L. B. Michaud, G. Hortobagyi, and V. Valero Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann. Onc., August 1, 2005; 16(8): 1289 - 1296. [Abstract] [Full Text] [PDF]

				R.-D. Hofheinz, B. von Gerstenberg-Helldorf, F. Wenz, U. Gnad, U. Kraus-Tiefenbacher, A. Muldner, R. Hehlmann, S. Post, A. Hochhaus, and F. Willeke Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1350 - 1357. [Abstract] [Full Text] [PDF]

				M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF]

				M. de Bruin, G. J. Peters, R. Oerlemans, Y. G. Assaraf, A. J. Masterson, A. D. Adema, B. A. C. Dijkmans, H. M. Pinedo, and G. Jansen Sulfasalazine Down-Regulates the Expression of the Angiogenic Factors Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase and Interleukin-8 in Human Monocytic-Macrophage THP1 and U937 Cells Mol. Pharmacol., October 1, 2004; 66(4): 1054 - 1060. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]

				Y.-L. Chung, H. Troy, I. R. Judson, R. Leek, M. O. Leach, M. Stubbs, A. L. Harris, and J. R. Griffiths Noninvasive Measurements of Capecitabine Metabolism in Bladder Tumors Overexpressing Thymidine Phosphorylase by Fluorine-19 Magnetic Resonance Spectroscopy Clin. Cancer Res., June 1, 2004; 10(11): 3863 - 3870. [Abstract] [Full Text] [PDF]

				N. Magne, J.-L. Fischel, A. Dubreuil, P. Formento, J. Ciccolini, J.-L. Formento, C. Tiffon, N. Renee, S. Marchetti, M.-C. Etienne, et al. ZD1839 (Iressa) Modifies the Activity of Key Enzymes Linked to Fluoropyrimidine Activity: Rational Basis for a New Combination Therapy with Capecitabine Clin. Cancer Res., October 15, 2003; 9(13): 4735 - 4742. [Abstract] [Full Text] [PDF]

				C. Rodel, Gerhard. G. Grabenbauer, T. Papadopoulos, W. Hohenberger, H.-J. Schmoll, and R. Sauer Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer J. Clin. Oncol., August 15, 2003; 21(16): 3098 - 3104. [Abstract] [Full Text] [PDF]

				J. Dunst, T. Reese, T. Sutter, H. Zuhlke, A. Hinke, K. Kolling-Schlebusch, and S. Frings Phase I Trial Evaluating the Concurrent Combination of Radiotherapy and Capecitabine in Rectal Cancer J. Clin. Oncol., October 1, 2002; 20(19): 3983 - 3991. [Abstract] [Full Text] [PDF]

				C. Blanquicett, G. Y. Gillespie, L. B. Nabors, C. R. Miller, S. Bharara, D. J. Buchsbaum, Robert. B. Diasio, and M. R. Johnson Induction of Thymidine Phosphorylase in Both Irradiated and Shielded, Contralateral Human U87MG Glioma Xenografts: Implications for a Dual Modality Treatment Using Capecitabine and Irradiation Mol. Cancer Ther., October 1, 2002; 1(12): 1139 - 1145. [Abstract] [Full Text] [PDF]

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				E. Ortmann and G. Hohenberg Treatment Side Effects: Case 1. Radiation Recall Phenomenon After Administration of Capecitabine J. Clin. Oncol., July 1, 2002; 20(13): 3029 - 3030. [Full Text] [PDF]

				J.-H. Lee, J.-H. Lee, J.-H. Ahn, H. Bahng, T.-W. Kim, Y.-K. Kang, K.-H. Lee, J.-C. Kim, C.-S. Yu, J.-H. Kim, et al. Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report J. Clin. Oncol., April 1, 2002; 20(7): 1751 - 1758. [Abstract] [Full Text] [PDF]

				R. B. Diasio An Evolving Role for Oral Fluoropyrimidine Drugs J. Clin. Oncol., February 15, 2002; 20(4): 894 - 896. [Full Text] [PDF]